Investigating metformin's effects on immune health in people with and without HIV who use injection drugs
Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use
This study is looking at how the diabetes medication metformin might help improve the immune system in people living with HIV and those who use injectable drugs, by reducing inflammation and boosting certain immune cells, to help lower their risk of infections and other health problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11195633 on NIH RePORTER |
What this research studies
This research explores how metformin, a medication commonly used for diabetes, can help restore immune balance in individuals with HIV and those who inject drugs. The study focuses on the immune system's response, particularly looking at inflammation and B cell function, which can be disrupted in these populations. By examining the effects of metformin, the research aims to address the heightened risk of infections and other health issues associated with both HIV and injection drug use. Participants will be monitored for changes in their immune health over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates include individuals living with HIV and those who inject drugs, particularly those experiencing immune system challenges.
Not a fit: Patients who do not have a history of injection drug use or HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immune health and reduced complications for individuals affected by HIV and injection drug use.
How similar studies have performed: Previous research has shown promise in using metformin for immune modulation, but this specific application in the context of HIV and injection drug use is relatively novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kobie, James J — University of Alabama at Birmingham
- Study coordinator: Kobie, James J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.